Biomedical Engineering Reference
In-Depth Information
. 35.. Robertson,. J.S.,. and. Grifiths,. E.,.Assuring. the. quality,. safety,. and. eficacy. of. DNA. vaccines,.
Methods Mol. Med.,
127,.363,.2006.
. 36.. Franceschi,. S.,. et. al.,. Human. papillomavirus. and. risk. factors. for. cervical. cancer. in. Chennai,.
India:.a.case-control.study,.
Int. J. Cancer,
.107,.127,.2003.
. 37.. Bosch,.F.X.,.et.al.,.Prevalence.of.human.papillomavirus.in.cervical.cancer:.a.worldwide.perspec-
tive.. International. Biological. Study. on. Cervical. Cancer. (IBSCC). Study. Group,
J. Natl. Cancer
Inst.,
.
87,
.796,.1995.
. 38.. Munoz,.N.,.et.al.,.Against.which.human.papillomavirus.types.shall.we.vaccinate.and.screen?.
The.international.perspective,.
Int. J. Cancer,
.111,.278,.2004.
. 39.. Hildesheim,.A.,.et.al.,.Risk.factors.for.rapid-onset.cervical.cancer,.
Am. J. Obstet. Gynecol.,
.180,.
517,.1999.
. 40.. de.Villiers,.E.M.,.Taxonomic.classiication.of.papillomaviruses,.
Papillomavirus Rep.
,.12,.57,.2001.
. 41.. FUTURE. II. Study. Group,. Prophylactic. eficacy. of. a. quadrivalent. human. papillomavirus.
(HPV).vaccine.in.women.with.virological.evidence.of.HPV.infection,.
J. Infect. Dis.,
196,.1438,.
2007.
. 42.. Peng,. S.,. et. al.,. Characterization. of. HLA-A2-restricted. HPV-16. E7-speciic. CD8(+). T-cell.
immune.responses.induced.by.DNA.vaccines.in.HLA-A2.transgenic.mice,.
Gene Ther.,
.13,.67,.
2006.
. 43.. Lin,.C.T.,.et.al.,.A.DNA.vaccine.encoding.a.codon-optimized.human.papillomavirus.type.16.E6.
gene.enhances.CTL.response.and.anti-tumor.activity,.
J. Biomed. Sci.
,
13,.481,.2006.
. 44.. Sallberg,. M.,. Frelin,. L.,. and. Weiland,. O.,. DNA. vaccine. therapy. for. chronic. hepatitis. C. virus.
(HCV).infection:.immune.control.of.a.moving.target,.
Expert Opin. Biol. Ther.,
9,.805,.2009.
. 45.. Low,.L.,.et.al.,.DNA.vaccination.with.electroporation.induces.increased.antibody.responses.in.
patients.with.prostate.cancer,.
Hum. Gene Ther.
,.20,.1269,.2009.
. 46.. De.las.Alas,.M.,.and.Steinhardt,.R.,.Phase.I.study.of.preventive.HIV.vaccine.shows.improved.
immune. responses. when. the. vaccine. is. delivered. by. electrical. impulses,. ICHOR. Medical.
Systems,.November.30,.2009,.www.ichorms.com/images/Release11-30-09.pdf.(accessed.March.
17,.2010).
. 47.. Rice,. J.,. Ottensmeier,. C.H.,. and. Stevenson,. F.K.,. DNA. vaccines:. precision. tools. for. activating.
effective.immunity.against.cancer,.
Nat. Rev. Cancer
,.8,.108,.2008.
. 48.. Laddy,. D.J.,. et. al.,. Electroporation. of. synthetic. DNA. antigens. offers. protection. in. nonhuman.
primates.challenged.with.highly.pathogenic.avian.inluenza.virus,.
J. Virol.,
83,.4624,.2009.
. 49.. Rabussay,. D.,. Applicator. and. electrode. design. for.
in vivo
. DNA. delivery. by. electroporation,.
Methods Mol. Biol.,
423,.35,.2008.
. 50.. Cai,. Y.,. et. al.,. Production. of. pharmaceutical-grade. plasmids. at. high. concentration. and. high.
supercoiled.percentage,.
Vaccine
,.28,.2046,.2010.
